文献速递脊柱关节炎

抗TNF治疗对中轴型脊柱关节炎相关疲劳的影响:BSRBR-AS注册研究与荟萃分析

Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

基于英国BSRBR-AS注册研究中998例有完整疲劳数据的中轴型脊柱关节炎患者,比较310例起始抗TNF治疗者与未起始者在1年随访时的疲劳变化,并进行倾向评分匹配和荟萃分析。结果显示抗TNF治疗可使疲劳评分适度改善,基线睡眠质量差者更可能获益。

要点

  • 抗TNF治疗1年可使axSpA患者疲劳评分较未治疗者多降低3.0分。
  • 荟萃分析显示抗TNF治疗显著改善疲劳,SMD=0.36(95%CI 0.15, 1.56)。
  • 基线睡眠质量差是抗TNF治疗后疲劳改善的预测因素。

核心结论

  • 抗TNF治疗可使axSpA患者疲劳获得显著但适度的改善。
  • 基线睡眠质量差者最可能报告疲劳改善。
  • 有效管理疲劳可能需联合其他方法。

研究设计与样本

  • 英国BSRBR-AS注册研究前瞻性招募axSpA患者,比较起始抗TNF者与未起始者1年内疲劳变化。
  • 使用倾向评分匹配调整组间差异,并与现有文献进行荟萃分析。
  • 在起始抗TNF且有临床相关疲劳者中分析基线预测因素。

主要发现

  • 998例有完整疲劳数据的BSRBR-AS招募者中310例起始抗TNF治疗。
  • 1年随访时,起始抗TNF组疲劳平均变化为-2.6分(95%CI -4.1, -1.9),未起始组平均加重0.2分。
  • 倾向评分调整后,起始抗TNF者疲劳较未起始者多降低3.0分。
  • 在显著疲劳且起始抗TNF者中,基线睡眠质量差预测疲劳改善。
  • 荟萃分析纳入1109例受试者,抗TNF治疗显著改善疲劳(SMD=0.36,95%CI 0.15, 1.56)。

关键数值与推荐

  • 疲劳采用Chalder疲劳量表测量。
  • 荟萃分析合并效应量SMD=0.36(95%CI 0.15, 1.56)。

临床怎么用

  • 对axSpA相关疲劳患者,抗TNF治疗可带来适度改善。
  • 基线睡眠质量差者可优先考虑抗TNF治疗以期疲劳改善。
  • 疲劳管理可能需要联合非药物或其他干预措施。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Effective management of axial spondyloarthritis (axSpA)-related fatigue is a major unmet clinical need. Anti-TNF therapy may reduce fatigue levels, although any effect has yet to be definitively quantified and predictors of any such improvements are unknown. METHODS: The British Society of Rheumatology Register in Axial Spondyloarthritis (BSRBR-AS) prospectively recruited axSpA patients across the UK. Changes in fatigue levels (measured using the Chalder Fatigue Scale) >1 year were compared between those starting anti-TNF therapy at the time of recruitment and those not. Differences between treatment groups were adjusted using propensity score matching. Results were meta-analysed with the extant literature to calculate pooled estimates. Then, among those BSRBR-AS anti-TNF commencers with clinically relevant fatigue, baseline predictors of response were investigated. RESULTS: Of the 998 BSRBR-AS recruits with complete fatigue data, 310 were anti-TNF commencers. At 1-year follow-up, the former group reported a mean fatigue change of -2.6 (95% CI -4.1, -1.9) points while the latter reported a mean worsening of fatigue by 0.2 points. Following propensity score adjustment, those commencing anti-TNF therapy reduced fatigue by 3.0 points compared with those not. Of those with significant fatigue and commencing anti-TNF, poor sleep quality at baseline predicted fatigue improvement. In the meta-analysis, including 1109 subjects, treatment with anti-TNF therapy resulted in a significant improvement in fatigue [Standardized mean difference (SMD) = 0.36, 95% CI 0.15, 1.56]. CONCLUSION: Anti-TNF therapy results in a significant but modest reduction in fatigue amongst axSpA patients, with those reporting poor sleep quality most likely to report improvement. Effective management will likely require additional approaches.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Shim J, Dean LE, Karabayas M, et al. Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis. Rheumatology (Oxford). 2020. PMID: 32337555. doi:10.1093/rheumatology/keaa132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。